How Many Pricing Hearings Add Up To Action On Pricing Transparency?
Mylan’s discussion of how the drug supply chain absorbs pricing for EpiPen raised more questions than it answered during a House Oversight Committee hearing
You may also be interested in...
PhRMA has released new data on where gross and net drug expenditure ends up along the pharmaceutical supply chain, which will support its position the debate over US drug pricing.
More than one-third of gross sales for brands is eaten up by rebates, discounts and fees, a study finds, raising questions about whether price concessions provided to payers are ‘flowing to patients,’ PhRMA President Stephen Ubl says.
Few would argue that 2016 threw a number of curveballs into the global arena. With the New Year upon us, Scrip took a deep breath and asked a number of internal and external contributors across the pharma and biotech spectrum for their expectations for 2017.